Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Molecular Allergy
Published in: Clinical and Molecular Allergy 1/2017

Open Access 01-12-2017 | Review

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis

Authors: Carlo Lombardi, Valerie Melli, Cristoforo Incorvaia, Erminia Ridolo

Published in: Clinical and Molecular Allergy | Issue 1/2017

Login to get access

Abstract

Allergic rhinitis has a very high burden regarding both direct and indirect costs. This makes essential in the management of AR to reduce the clinical severity of the disease and thus to lessen its costs. This particularly concerns allergen immunotherapy (AIT), that, based on its immunological action on the causes of allergy, extends its benefit also after discontinuation of the treatment. From the pharmacoeconomic point of view, any treatment must be evaluated according to its cost-effectiveness, that is, the ratio between the cost of the intervention and its effect. A favorable cost-benefit ratio for AIT was defined, starting from the first studies in the 1990s on subcutaneous immunotherapy (SCIT) in AR patients, that highlighted a clear advantage on costs over the treatment with symptomatic drugs. Such outcome was confirmed also for sublingual immunotherapy (SLIT), that has also the advantage on SCIT to be free of the cost of the injections. Here we review the available literature on pharmacoeconomic data for SLIT with the 5-grass pollen tablets.
Literature
1.
The International Study of Asthma and Allergies in Childhood (ISAAC). Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhino conjunctivitis, and atopic eczema. Lancet. 1998;351:1225–32.CrossRef
2.
Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol. 1999;82:233–48.CrossRefPubMed
3.
Upton MN, McConnachie A, McSharry C, et al. Intergenerational 20 year trends in the prevalence of asthma and hay fever in adults: the Midspan family study survey of parents and offspring. BMJ. 2000;321:88–92.CrossRefPubMedPubMedCentral
4.
Linneberg A, Nielsen NH, Madsen F, et al. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional studies 8 years apart; the Copenhagen Allergy Study. J Allergy Clin Immunol. 2000;106:247–52.CrossRefPubMed
5.
Dalal AA, Stanford R, Henry H, et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol. 2008;101:23–9.CrossRefPubMed
6.
Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis. Pharmacoeconomics. 2004;22:345–61.CrossRefPubMed
7.
Mackowiak JI. The health and economic impact of rhinitis. Am J Manag Care. 1997;3:S8–18.
8.
Medical expenditure panel survey. Statistical brief #204: allergic rhinitis: trends in use and expenditures, 2000 and 2005. 2008. http://​www.​meps.​ahrq.​gov/​mepsweb/data_files/publications/st204/stat204.pdf.
9.
Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-year retrospective study. Eur Respir J. 2003;21:116–22.CrossRefPubMed
10.
Marcellusi A, Viti R, Incorvaia C, et al. Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study. Recenti Prog Med. 2015;106:517–27.PubMed
11.
Price D, Scadding G, Ryan D, et al. The hidden burden of adult allergy rhinitis: UK healthcare resource utilisation survey. Clin Transl Allergy. 2015;5:39.CrossRefPubMedPubMedCentral
12.
Arnold RJG, Ekins S. Time for cooperation in health economics among the modelling community. Pharmacoeconomics. 2010;28:609–13.CrossRefPubMed
13.
Bleichrodt H, Quiggin J. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ. 1999;18:681–708.CrossRefPubMed
14.
Vuurman EF, van Veggel LM, Uitenwijk MM, et al. Seasonal allergic rhinitis and antihistamine effect on children’s learning. Ann Allergy. 1993;71:121–6.PubMed
15.
Bousquet J, Lockey RF, Malling HJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998;53(Suppl 44):4–30.
16.
Buchner K, Siepe M. Nutzen der Hyposensibilierung unter wirtschaftlichen Aspekten. Allergo J. 1995;4:156–63.
17.
Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics. 2000;17:37–52.CrossRefPubMed
18.
Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol. 2005;33:296–302.CrossRef
19.
Ariano R, Berto P, Tracci D, et al. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc. 2006;27:159–63.PubMed
20.
Omnes LF, Bousquet J, Scheinmann P, et al. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Eur Ann Allergy Clin Immunol. 2007;39:148–56.PubMed
21.
Hankin C, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol. 2008;121:227–32.CrossRefPubMed
22.
Hankin C, Cox L, Lang D, et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010;104:79–85.CrossRefPubMed
23.
Wang Z, Hankin CS, Cox L, Bronstone A. Allergen immunotherapy significantly reduces healthcare costs among US adults with allergic rhinitis: a retrospective matched cohort study jointly funded by the AAAAI and ACAAI. J Allergy Clin Immunol. 2011;127(2):150.
24.
Hankin CS, Cox L, Bronstone A, et al. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2013;131:1084–91.CrossRefPubMed
25.
Berto P, Bassi M, Incorvaia C, et al. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Eur Ann Allergy Clin Immunol. 2005;37:303–8.PubMed
26.
Berto P, Frati F, Incorvaia C. Economic studies of immunotherapy: a review. Curr Opin Allergy Clin Immunol. 2008;8:585–9.CrossRefPubMed
27.
Podladnikova J, Krcmova I, Vicek J. Economic evaluation of sublingual vs. subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol. 2008;100:482–9.CrossRef
28.
Didier A, Malling HJ, Worm M, et al. Optimal dose, effectiveness, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338–45.CrossRefPubMed
29.
Didier A, Worm M, Horak F, et al. Sustained-3-year effectiveness of pre- and co-seasonal 5-grass pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128:559–66.CrossRefPubMed
30.
Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130:1327–34.CrossRefPubMed
31.
Ciprandi G. A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablets is recognized also in Italy. J Asthma Allergy. 2015;8:25–7.PubMedPubMedCentral
32.
Ruggeri M, Oradei M, Frati F, Puccinelli P, et al. Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults. Clin Drug Investig. 2013;33:343–9.CrossRefPubMedPubMedCentral
33.
Westerhout KY, Verheggen BG, Schreder CH, et al. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ. 2012;15:906–17.CrossRefPubMed
34.
Verheggen BG, Westerhout KY, Schreder CH, et al. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clin Transl Allergy. 2015;5:1.CrossRefPubMedPubMedCentral
35.
Bachert C, Noergaard Andreasen J. Cost-effectiveness of immunotherapy in the treatment of seasonal allergic rhinitis: identifying product-specific parameters of relevance for health care decision-makers and clinicians. Int Arch Allergy Immunol. 2015;168:213–7.CrossRefPubMed
36.
French C, Seiberling K. Comparative costs of subcutaneous and sublingual immunotherapy. Curr Opin Otolaryngol Head Neck Surg. 2015;23:226–9.CrossRefPubMed
37.
Cox L. Allergy immunotherapy in reducing healthcare cost. Curr Opin Otolaryngol Head Neck Surg. 2015;23:247–54.CrossRefPubMed
38.
Rønborg S, Johnsen CR, Theilgaard S, et al. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark. J Med Econ. 2016;19:735–41.CrossRefPubMed
39.
Incorvaia C, Mauro M, Leo G, et al. Adherence to sublingual immunotherapy. Curr Allergy Asthma Rep. 2016;16:12.CrossRefPubMed
Metadata
Title
Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
Authors
Carlo Lombardi
Valerie Melli
Cristoforo Incorvaia
Erminia Ridolo
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Clinical and Molecular Allergy / Issue 1/2017
Electronic ISSN: 1476-7961
DOI
https://doi.org/10.1186/s12948-017-0058-3

Other articles of this Issue 1/2017

Clinical and Molecular Allergy 1/2017 Go to the issue

Research

Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia

Case Report

Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature

Review

Immunosenescence in aging: between immune cells depletion and cytokines up-regulation

Research

Sensitization to secretoglobin and lipocalins in a group of young children with risk of developing respiratory allergy

Review

Hypersensitivity pneumonitis: a complex lung disease

Review

Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms